Antihistamines News and Research

RSS

Ranbaxy receives tentative FDA approval for Fexofenadine hydrochloride tablets

Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), has announced that RLL has received tentative approval from the U.S. Food and Drug Administration to manufacture and market the antihistamine Fexofenadine Hydrochloride Tablets, 30 mg, 60 mg, and 180 mg.

18 May 2007

Right medications essential for allergy control

Choosing the right medications is essential to gaining control over symptoms as allergy season comes into full bloom, allergy specialists at UT Southwestern Medical Center warn.

10 May 2007

New human medications found in fish in Texas

Baylor University researchers have found the residue of three new human medications in fish living in the Pecan Creek in North Texas.

2 May 2007

Schering-Plough announces European approval of new formulations of AERIUS (Desloratadine)

European Commission approves AERIUS Tablets (2.5 mg and 5 mg) and AERIUS Oral Solution (0.5 mg per 1ml).

30 Apr 2007

Mixing certain allergy medications with other medicines can have hazardous effects on your health

Allergy season is here, and over-the-counter allergy medications are flying off the shelves.

24 Apr 2007

Ranbaxy receives U.S. approval to market Loratadine Antihistamine tablets

Ohm Laboratories, a wholly owned subsidiary of Ranbaxy Laboratories Limited, has announced that Ranbaxy has received approval from the U. S. Food and Drug Administration to manufacture and commercialize its Loratadine Orally Disintegrating Tablets, 10mg. The antihistamine previously made the switch from the prescription to the OTC market.

15 Apr 2007

Gleevec available to patients in post-surgical GIST study

Investigators will begin offering Gleevec(R) (imatinib mesylate)* tablets to patients receiving placebo in a major North American clinical trial after an interim analysis showed participants with Kit-positive gastrointestinal stromal tumors treated with Gleevec following surgery were significantly less likely to experience a return of their cancer compared to those not taking this innovative therapy.

15 Apr 2007

Newborns with respiratory distress should be evaluated for primary ciliary dyskinesia

Reviewing published reports, Ferkol and Margaret Leigh, M.D., professor of pediatrics at the University of North Carolina at Chapel Hill (UNC), found that neonatal respiratory distress was a common clinical symptom of PCD, a chronic airway disease that affects about 1 in 15,000 children.

20 Feb 2007

Lung neutrophils produce histamine in significant quantities

In a surprise finding, scientists have discovered that histamine, the inflammatory compound released during allergic reactions that causes runny nose, watery eyes, and wheezing, can be produced in large amounts in the lung by neutrophils, the white blood cells that are the major component of pus.

14 Jan 2007

Toxic chemical found in 3 more medicines in Panama

A toxic chemical found in contaminated cough syrup suspected to have caused the deaths of 22 people in Panama, has now been found in three more medications made by a government-run factory in Panama.

19 Oct 2006

Adverse drug events means 700,000 end up in emergency departments

According to a recently released study every year, as many as 700,000 people end up in hospital emergency departments because they experience an adverse drug effect, and 117,000 of those have to be hospitalized.

19 Oct 2006

New York Times examines efforts to obtain FDA approval for Abraxane to treat earlier-stage cancer

The New York Times has examined efforts by the pharmaceutical company Abraxis BioScience to obtain FDA approval for its late-stage breast cancer drug Abraxane as a treatment for earlier-stage breast cancer.

5 Oct 2006

Thousands of prescription drug products sold in the U.S. not approved by FDA

Drugs that have not been approved by FDA make up nearly 2% of prescription drugs on the market, and some of them "might not only be ineffective but also might actually be harmful," USA Today reports.

20 Sep 2006

Popular antihistamine used to help young children sleep is ineffective

Although about half of pediatricians recommend that children under age 2 can be given diphenhydramine to help them sleep, the first study to look at effectiveness of the agent in children who are that young found no benefit.

4 Jul 2006

Benadryl does not improve infant sleep

An antihistamine often recommended to parents whose infants do not sleep through the night may not be effective in reducing nighttime awakenings or improving parents' happiness with their children's sleep.

3 Jul 2006

FDA approves Prezista (darunavir)

FDA approves Prezista (darunavir), a new drug for adults whose infection with the human immunodeficiency virus (HIV) has not responded to treatment with other antiretroviral drugs.

26 Jun 2006

St. John's wort and Echinacea increase activity of enzyme in the liver and intestine

St. John's wort and Echinacea, two widely-used herbal preparations, have been found to increase activity of a specific enzyme in the liver and intestine, an enzyme involved in the metabolization of roughly one in every four pharmaceutical drugs on the market today, reports a clinical pharmacologist at Indiana University School of Medicine.

11 Apr 2006

Inflammation cuts both ways

Inflammation cuts both ways. When invaded by an infectious agent, for example, the body calls on the forces of inflammation to fight and defeat the intruder.

6 Apr 2006

Immune response protects against brain tumor development

In their quest to determine whether immune system surveillance guards against brain tumor development, researchers at The University of Texas M. D. Anderson Cancer Center have found that allergies and asthma that stimulate inflammation may be protective, but use of antihistamines to control the inflammation could eliminate that protection.

4 Apr 2006

Study shows new atopic dermatitis therapy significantly delays onset of flares

Stiefel Laboratories, the world's largest independent pharmaceutical company specializing in dermatology, announced that a recent study shows MimyX Cream extends the remission period of atopic dermatitis (AD) by 48 percent when used in conjunction with an emollient compared to emollient alone.

6 Mar 2006